Home >> Company >> RANBAXY LAB.
09 Mar, 2013
Ranbaxy gets reprieve on atorvastatin recall
A New Jersey federal judge has saved Ranbaxy from a class action's demand for a wider recall of its atorvastatin drug.
Source: DNA Money
Click here for the full article.27 Feb, 2013
Ranbaxy slips further as Q4 results disappoint street
Ranbaxy shares tumbled 4 percent on Wednesday morning, extending Tuesday's losses on a surprise fourth quarter loss on the back of falling sales and costs related to the recall of its cholesterol lowering drug in the US market.
Source: Moneycontrol.com
Click here for the full article.27 Feb, 2013
Ranbaxy posts Rs 492-cr net loss in Q4
Pharma major Ranbaxy Laboratories on Tuesday reported a consolidated net loss of Rs 492 crore for the fourth quarter ended December 31, mainly due to its voluntary recall of Atorvastatin calcium t...
Source: The Hindu Business Line
Click here for the full article.25 Feb, 2013
Ranbaxy restarts generic Lipitor production
Ranbaxy has restarted the production of its anti-cholestrol drug Atorvastatin for the United States market. The company had, in November 2012, voluntarily recalled select batches and str...
Source: The Hindu Business Line
Click here for the full article.25 Feb, 2013
Ranbaxy up on restart of Atorvastatin production in the US
Ranbaxy shares rose over 4 percent in morning trade after the drug maker said it has resumed production of the drug substance for its Atorvastatin cholesterol lowering drug in United States.
Source: Moneycontrol.com
Click here for the full article.25 Feb, 2013
HSBC ups Ranbaxy to overweight on generic Lipitor announcement
HSBC raised its rating on shares of Ranbaxy Laboratories Ltd to 'overweight' from 'underweight' after the Indian drugmaker said it would resume production of a generic version of cholesterol fighter
Source: Sify.com
Click here for the full article.25 Feb, 2013
HSBC ups Ranbaxy to 'overweight' on generic Lipitor announcement
HSBC raised its rating on shares of Ranbaxy Laboratories Ltd to 'overweight' from 'underweight' after the Indian drug-maker said it would resume production of a generic version of cholesterol fighter ...
Source: NDTVPROFIT.com
Click here for the full article.20 Feb, 2013
Credit Suisse upgrades Ranbaxy to 'neutral'
Credit Suisse upgrades Ranbaxy Laboratories Ltd to "neutral" from "underperform". The investment bank says the possible penalty related to the recall of generic Lipitor last year in the United
Source: Sify.com
Click here for the full article.16 Jan, 2013
Ranbaxy, Daiichi Sankyo to leverage synergies
Both the companies intend to integrate their business operations in Thailand to leverage and maximise the synergies of hybrid business model, which is expected to commence business on April 1, 2013, Ranbaxy said in a statement on Wednesday.
Source: Rediff.com
Click here for the full article.03 Jan, 2013
Ranbaxy's Lipitor share dives after recall
Ranbaxy Laboratories' share in generic Lipitor in the US market has dropped drastically following a recall of the drug in November and its subsequent production halt.
Source: DNA Money
Click here for the full article.